This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Related letters  • Similar articles in JAMA  Topic Collections  • Cardiovascular System, Other  • Cardiovascular System  • Radiologic Imaging  • Renal Diseases  • Renal Diseases, Other  • Statistics and Research Methods  • Angiology  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: In response to Dr Burgess and colleagues, the formulation of sodium bicarbonate used in our study (and commonly used in clinical practice because of ease of preparation) was identical to that used by Merten et al¹ in the registry phase of their study, reportedly with excellent results. The formulation used in the trial phase of their study had a slightly higher sodium bicarbonate concentration, which would result in a 70-kg patient receiving an additional 15 mEq of sodium bicarbonate over the study period. This small difference did not appear to alter the outcomes between the trial and registry phases of their study, and we believe is unlikely to account for the lack of observed benefit in our study. Although measures of urine pH may have been informative, the optimal timing of testing and degree of change in urinary pH to confer a protective effect, if any, remains unknown. . . . [Full Text of this Article]

Somjot S. Brar, MD
sbrar@cvri.org
Center for Interventional Vascular Therapy
Columbia University Medical Center
New York, New York

Albert Yuh-Jer Shen, MD; Michael B. Jorgensen, MD
Department of Cardiology
Kaiser Permanente
Los Angeles, California

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Prevention of Contrast-Induced Nephropathy With Sodium Bicarbonate: A Randomized Controlled Trial
Gregory J. Merten, W. Patrick Burgess, Lee V. Gray, Jeremiah H. Holleman, Timothy S. Roush, Glen J. Kowalchuk, Robert M. Bersin, Arl Van Moore, Charles A. Simonton, III, Robert A. Rittase, H. James Norton, and Thomas P. Kennedy
JAMA. 2004;291(19):2328-2334.
ABSTRACT | FULL TEXT  

RELATED LETTERS

Sodium Bicarbonate vs Sodium Chloride in Preventing Contrast Medium–Induced Nephropathy
William Burgess, Gregory J. Merten, and Robert A. Rittase
JAMA. 2009;301(4):377.
EXTRACT | FULL TEXT  

Sodium Bicarbonate vs Sodium Chloride in Preventing Contrast Medium–Induced Nephropathy
Bradley D. Shy, Amit Gupta, and Robert S. Hoffman
JAMA. 2009;301(4):377-378.
EXTRACT | FULL TEXT  

Sodium Bicarbonate vs Sodium Chloride in Preventing Contrast Medium–Induced Nephropathy
Mehmet Kanbay, Benan Kasapoglu, and Ali Akcay
JAMA. 2009;301(4):378.
EXTRACT | FULL TEXT  

Sodium Bicarbonate vs Sodium Chloride in Preventing Contrast Medium–Induced Nephropathy
Alberto Bouzas-Mosquera, José M. Vázquez-Rodríguez, and Jesús Peteiro
JAMA. 2009;301(4):378-379.
EXTRACT | FULL TEXT